Drug Profile
Vatalanib
Alternative Names: CGP 79787; PTK 787; PTK/ZK; vatalanib-succinate; ZK 222584Latest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Bayer Schering Pharma; Novartis
- Developer Novartis
- Class Antineoplastics; Phthalazines; Pyridazines; Pyridines; Small molecules
- Mechanism of Action Angiogenesis inhibitors; Macrophage colony stimulating factor receptor antagonists; Platelet-derived growth factor beta receptor antagonists; Proto oncogene protein c-kit inhibitors; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Age-related macular degeneration; Colorectal cancer; Glioblastoma; Multiple myeloma; Non-small cell lung cancer; Ovarian cancer; Renal cancer; Solid tumours
Most Recent Events
- 29 May 2008 Novartis Pharmaceuticals in collaboration with Dana-Farber Cancer Institute terminates a phase I trial in Solid tumors in the US (NCT00358163)
- 29 Apr 2008 Discontinued - Phase-I for Ovarian cancer in Germany (PO)
- 29 Apr 2008 Discontinued - Phase-I for Renal cancer in Germany (PO)